Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Publication Type:

Journal Article


Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 16, Issue 21, p.5260-8 (2010)


2010, Adult, Aged, Antineoplastic Agents, CARCINOMA, Carcinoma, Medullary, Cell Differentiation, Center-Authored Paper, Clinical Research Division, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Fluorodeoxyglucose F18, Humans, Indoles, Iodine, Male, Middle Aged, Neoplasm Metastasis, Positron-Emission Tomography, Pyrroles, Thyroid Neoplasms, Tomography, Emission-Computed, Treatment Failure


We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)-avid, iodine-refractory well-differentiated thyroid carcinoma (WDTC) and medullary thyroid cancer (MTC) and to assess for early response per FDG-PET.